Spaceflight = Programmed Anemia?

#Anemia #Space #Microgravity #Hemolysis #RBC #Astronauts  


Space anemia is a well-known phenomenon among astronauts, observed since the earliest manned missions. It is characterized by a decrease in red blood cell count and hemoglobin concentration, which can affect oxygen transport capacity, physical performance, and post-flight recovery. Until recently, this anemia was considered transient and adaptive—primarily due to early changes in plasma volume and a temporary reduction in erythropoiesis linked to microgravity.  

However, new clinical data show that anemia persists well beyond the first few weeks of spaceflight—and sometimes for several months after return. These findings suggest the presence of an active and prolonged pathological mechanism that could significantly impact astronaut health.  

Against this backdrop, this study aimed to determine whether hemolysis—i.e., increased destruction of red blood cells—is a central mechanism in persistent space anemia.  

Does space destroy our red blood cells?

The results showed a 54% increase in CO elimination during spaceflight, indicating persistent hemolysis throughout the mission. This hemolysis was still observed on day 157—well beyond the initial fluid shift adaptations. It appeared to be independent of both erythropoietin (EPO) levels and plasma volume changes.  

Additionally, blood markers associated with hemoglobin breakdown were consistently elevated in space, pointing to increased hemolysis. Four days after return, these markers dropped significantly, reflecting a return to Earth’s gravity. However, even a year later, some indicators remained altered: exhaled CO was still 30% higher, reticulocytes had increased by 16%, and hemoglobin concentration was 3.5% higher. These results confirm that microgravity has long-lasting effects on erythropoietic regulation.  

Flying—but at what cost?

Space anemia is a well-documented effect of human spaceflight, marked by a reduction in red blood cells during and after orbital missions. Previously considered a short-term adaptation to microgravity, it can in fact persist beyond the initial weeks in space—and even months after returning to Earth. One of the major challenges lies in understanding its long-lasting mechanisms.  

This study set out to determine whether hemolysis plays a central role in space anemia. The findings reveal a significant and sustained increase in hemolysis throughout the entire mission, independent of fluid shifts or EPO levels. Even one year post-flight, key biomarkers remain partially altered, suggesting a lasting impact of microgravity on erythrocyte homeostasis.  

These results pave the way for new research into hematological adaptations in space. They highlight the urgent need for targeted monitoring and countermeasures to preserve red blood cell integrity during long-duration missions—especially with future crewed missions to Mars on the horizon.  

Read next: Anemia in patients with type 2 diabetes and renal failure